公开(公告)号：US20220242851A1

公开(公告)日：2022-08-04

申请号：US17620464

申请日：2020-06-19

Applicant: SHENZHEN JINRUI FOUNDATION BIOTECH CO., LTD ,  MEDSHINE DISCOVERY INC.

Inventor： Kevin X. CHEN ,  Li ZHANG ,  Kai ZHOU ,  Yanxin YU ,  Boyu HU ,  Huiyu ZHANG

IPC: C07D403/12 ,  A61P35/00

Abstract: The present invention relates to a crystal form and a salt of a compound serving as a Pan-HER tyrosine kinase inhibitor and a preparation method therefor, and also use thereof in the preparation of a medicament for treating solid tumors.

公开(公告)号：US20230365558A1

公开(公告)日：2023-11-16

申请号：US18245551

申请日：2021-09-18

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Zuhao GUO ,  Yanxin YU ,  Boyu HU ,  Jingjing WANG ,  Zhaoguo CHEN ,  Cheng XIE ,  Jian XIONG ,  Yongbo FANG ,  Yingtao LIU ,  Jian LI ,  Shuhui CHEN

IPC: C07D471/04 ,  C07D413/12 ,  C07D498/04 ,  C07D498/10 ,  C07D401/12 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D413/12 ,  C07D498/04 ,  C07D498/10 ,  C07D401/12 ,  A61P35/00 ,  C07B2200/13

Abstract: A series of tetrahydroisoquinoline derivatives and the crystal forms thereof. Specifically disclosed are a compound as represented by formula (VII), a crystal form thereof, and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230055321A1

公开(公告)日：2023-02-23

申请号：US17778533

申请日：2020-11-20

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Shanghua XIA ,  Zhaoguo CHEN ,  Zuhao GUO ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Li ZHANG ,  Fen JIANG ,  Jingjing WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: A61K31/519 ,  C07D519/00 ,  A61K45/06 ,  A61K31/55

Abstract: Provided are a class of DNA-PK inhibitor, and specifically, a compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of DNA-PK inhibitor-related drugs.

公开(公告)号：US20210078958A1

公开(公告)日：2021-03-18

申请号：US16955510

申请日：2018-12-19

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X. CHEN ,  XiaWei WEI ,  Li ZHANG ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Zhaoguo CHEN ,  Huiyu ZHANG ,  Shuhui CHEN

IPC: C07D239/94 ,  C07D409/12 ,  C07D413/12 ,  C07D403/12 ,  C07D405/12 ,  C07D401/12 ,  C07D413/14 ,  C07D498/04 ,  C07D405/14 ,  C07D409/14

Abstract: The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

公开(公告)号：US20210024538A1

公开(公告)日：2021-01-28

申请号：US16968206

申请日：2019-01-29

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Jian Xiong ,  Jingjing WANG ,  Boyu HU ,  Haizhong TAN ,  KEVIN X CHEN ,  jIAN li ,  Shuhui CHEN

IPC: C07D495/04

Abstract: A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug.

公开(公告)号：US20230026616A1

公开(公告)日：2023-01-26

申请号：US17779322

申请日：2020-11-25

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Shanghua XIA ,  Zhaoguo CHEN ,  Zuhao GUO ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Li ZHANG ,  Fen JIANG ,  Jingjing WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: C07D519/00 ,  A61P35/00 ,  A61K45/06

Abstract: A class of DNA-PK inhibitors, in particular a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug relating to a DNA-PK inhibitor.

公开(公告)号：US20200339568A1

公开(公告)日：2020-10-29

申请号：US16760740

申请日：2018-11-02

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Zhaoguo CHEN ,  Li ZHANG ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Xiaofei WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

公开(公告)号：US20210323979A1

公开(公告)日：2021-10-21

申请号：US17053076

申请日：2019-05-08

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Fen JIANG ,  Xinde CHEN ,  Li ZHANG ,  Zhaoguo CHEN ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Cheng XIE ,  Shuhui CHEN

IPC: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200231597A1

公开(公告)日：2020-07-23

申请号：US16635916

申请日：2018-07-27

Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Kai ZHOU ,  Yanxin YU ,  Boyu HU ,  Linghui WU ,  Xiaoyuan CHEN ,  Jiangfeng LIN ,  Haomin CHEN ,  Xiangjian WANG ,  Xiquan ZHANG ,  Xin TIAN ,  Hongjiang XU

IPC: C07D495/04

Abstract: A bicyclic compound acting as a RORγ inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good RORγ inhibitory activities, being expected to be used for treating diseases mediated by RORγ receptors in a mammal.

公开(公告)号：US20200010467A1

公开(公告)日：2020-01-09

申请号：US16305414

申请日：2017-06-02

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Boyu HU ,  Charles Z. DING ,  Zhigang HUANG ,  Ruibin LIN ,  Minliang XIAO ,  Jinsheng XIE ,  Shuhui CHEN ,  Cheng LI

IPC: C07D471/08 ,  A61P31/04

Abstract: Disclosed in the present invention is a type of novel β-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.